Results 121 to 130 of about 492 (136)
Pharmacological Research, 2017 We investigated a pulmonary adverse drug reaction possibly induced by fluoxetine, the Interstitial Lung Disease, by performing a systematic review of published case reports on this subject, a review of the World Health Organization VigiAccess database, of the European EudraVigilance database and of a national Pharmacovigilance database (Italian ...
Maria Del Zompo +2 more
exaly +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Safety study on adverse events of zanubrutinib based on WHO-VigiAccess and FAERS databases
Expert Opinion on Drug SafetyThe study endeavors to elucidate AE signals associated with zanubrutinib data from the WHO-VigiAccess and FAERS databases. The aim is to furnish robust scientific evidence to inform clinical practice and regulatory decisions.We meticulously extracted all AE breports tied to zanubrutinib from the both databases, encompassing the period from the drug's ...
Cong Liang
exaly +3 more sources
Expert Opinion on Drug Safety
This study aimed to provide an overview of gastrointestinal (GI) adverse events associated with immune checkpoint inhibitors (ICIs) using two pharmacovigilance databases, EudraVigilance and VigiAccess.Data was collected from the date of ICI's marketing authorization until 30 November 2023.
Mandeep Kumar Arora +2 more
exaly +3 more sources
This study aimed to provide an overview of gastrointestinal (GI) adverse events associated with immune checkpoint inhibitors (ICIs) using two pharmacovigilance databases, EudraVigilance and VigiAccess.Data was collected from the date of ICI's marketing authorization until 30 November 2023.
Mandeep Kumar Arora +2 more
exaly +3 more sources
Journal of Clinical Oncology, 2019
e13118 Background: Immune checkpoint inhibitors (ICIs), especially ipilimumab (ipi) and nivolumab (nivo), have received approvals from the U.S. Food and Drug Administration for the treatment of multiple tumor types. These medications have shown great promise in the treatment of several malignancies but are associated with immune-related adverse ...
Nikita Nikita +5 more
openaire +1 more source
e13118 Background: Immune checkpoint inhibitors (ICIs), especially ipilimumab (ipi) and nivolumab (nivo), have received approvals from the U.S. Food and Drug Administration for the treatment of multiple tumor types. These medications have shown great promise in the treatment of several malignancies but are associated with immune-related adverse ...
Nikita Nikita +5 more
openaire +1 more source
Journal of Nephrology
Sparsentan represents a major advancement in the treatment of proteinuric kidney diseases, offering a promising option to improve patient outcomes and slow disease progression. Evaluation of its safety profile is essential to support its long-term integration into clinical practice.This study employed a retrospective descriptive analysis combined with ...
Hongxuan Fan +4 more
openaire +2 more sources
Sparsentan represents a major advancement in the treatment of proteinuric kidney diseases, offering a promising option to improve patient outcomes and slow disease progression. Evaluation of its safety profile is essential to support its long-term integration into clinical practice.This study employed a retrospective descriptive analysis combined with ...
Hongxuan Fan +4 more
openaire +2 more sources
Descriptive Analysis of Adverse Drug Events of Three mTOR Inhibitors Using WHO-VigiAccess
Current Drug SafetyIntroduction: The mechanistic target of rapamycin (mTOR) pathway regulates cell growth, metabolism, and survival. Its dysregulation contributes to cancer, autoimmune disorders, neurodegeneration, and aging. While mTOR inhibitors such as Sirolimus, Everolimus, and Temsirolimus are therapeutically valuable, they ...
Prerna Bhati +2 more
openaire +1 more source
A Real-world Study on Adverse Events Related to Mirogabalin Based on the VigiAccess Database
Proceedings of Anticancer ResearchObjective: To utilize the VigiAccess database for data mining to analyze the characteristics of adverse reactions induced by mirogabalin, providing critical information for clinical medication use. Method: This study analyzed data from the VigiAccess database, filtering out adverse reaction reports where mirogabalin was identified as the Primary ...
Shiliang Xi, Heqing Tang
openaire +1 more source
Cancer Biotherapy and Radiopharmaceuticals
Background: Radiopharmaceuticals are being used more frequently to treat neuroendocrine tumors and advanced prostate cancer; however, their clinical application is associated with adverse drug reactions (ADRs) that may affect patient safety.
Yiheng Jin +5 more
openaire +1 more source
Background: Radiopharmaceuticals are being used more frequently to treat neuroendocrine tumors and advanced prostate cancer; however, their clinical application is associated with adverse drug reactions (ADRs) that may affect patient safety.
Yiheng Jin +5 more
openaire +1 more source
Dermatological Health
Objective: This study aims to explore adverse events related to Technetium (Tc99m) Medronate using the VigiAccess database, uncover potential risk signals, and provide comprehensive reference for rational clinical drug use to ensure patient safety.
Weigang Liu, Qian Wu, Heqing Tang
openaire +1 more source
Objective: This study aims to explore adverse events related to Technetium (Tc99m) Medronate using the VigiAccess database, uncover potential risk signals, and provide comprehensive reference for rational clinical drug use to ensure patient safety.
Weigang Liu, Qian Wu, Heqing Tang
openaire +1 more source
Aims Fruquintinib, a highly selective small-molecule tyrosine kinase inhibitor targeting the vascular endothelial growth factors (VEGF)-1, -2, and -3, has demonstrated significant efficacy in prolonging progression-free survival and overall survival in patients with refractory metastatic colorectal cancer.
Qian Guo +5 more
openaire +1 more source
Qian Guo +5 more
openaire +1 more source